Abstract
Although type 2 diabetes and cancer are major health concerns among the adult population, few studies have directly addressed the relationship between the two, or the impact of diabetes on cancer outcomes. Diabetes and hyperglycemia are associated with an elevated risk of developing pancreatic, liver, colon, breast, and endometrial cancer. When treating cancer patients who have diabetes, clinicians must consider the cardiac, renal, and neurologic complications commonly associated with diabetes. Chemotherapeutic choices and, ultimately, the outcome for cancers may be affected by the avoidance of agents that have been shown to provide the best clinical response and survival in cancer patients without other disease complications. Evidence from population-based studies and clinical trials indicate that hyperglycemic and diabetic patients experience higher mortality and recurrence rates after diagnosis with, and treatment for, cancer. Evidence from the intensive care literature indicates that achieving glucose control leads to better clinical outcomes. If so, continued improvement of cancer outcomes may depend upon improved diabetes control. The association between diabetes and cancer is complex and warrants further study as the general population ages and the magnitude of both health problems continues to grow. Here we consider the influence of diabetes and hyperglycemia on the development, treatment, and long-term outcomes of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ko C and Chaudhry S (2002) The need for a multidisciplinary approach to cancer care. J Surg Res 105: 53–57
Rowland J et al. (2004) Cancer survivorship-United States, 1971–2001. MMWR 53: 526–529
Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. (2004) Rev ed Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 1–8. [http://www.cdc.gov/diabetes] (accessed 24 July 2004)
Williams RH (2002) Williams Textbook of Endocrinology. Philadelphia: WB Saunders Co.
Poulson J (1997) The management of diabetes in patients with advanced cancer. J Pain Symptom Manage 13: 339–346
Grimberg A and Cohen P (2000) Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183: 1–9
Rajah R et al. (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272: 12181–12188
Giovannucci E (2003) Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 35: 694–704
Saydah SH et al. (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157: 1092–1100
Ma J et al. (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96: 546–553
Muti P et al. (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11: 1361–1368
Hu FB et al. (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Nat Cancer Inst 91: 542–547
Nilsen TI and Vatten LJ (2001) Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinemia hypothesis. Br J Cancer 84: 417–422
Will JC et al. (1998) Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 147: 816–825
Adami HO et al. (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2: 307–314
Calle EE et al. (1998) Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 9: 403–410
Chow WH et al. (1995) Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 87: 930–931
Wideroff L et al. (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89: 1360–1365
Lagiou P et al. (2000) Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 92: 1096–1099
Michels KB et al. (2003) Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26: 1752–1758
Weiderpass E et al. (2002) Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 102: 258–261
Zendehdel K et al. (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Nat Cancer Inst 95: 1797–1800
Wildiers H et al. (2003) Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42: 1213–1242
Verstappen CC et al. (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63: 1549–1563
Bonadonna G and Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15
De Vita VT Jr et al. (1987) The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 47: 5810–5824
Schilsky RL (1982) Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 9: 75–83
Nichols CR (1998) Testicular cancer. Curr Probl Cancer 22: 187–274
Nesto RW (2003) The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 4 (Suppl 6): 511–518
Avogaro A et al. (2004) Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 93: 13A–16A
Theodoulou M and Seidman AD (2003) Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol 30: 730–739
Donnelly R et al. (2000) ABC of arterial and venous disease: vascular complications of diabetes. BMJ 320: 1062–1066
Vokes EE et al. (1993) Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 11: 360–368
Weiser MA et al. (2004) Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 100: 1179–1185
Meyerhardt JA et al. (2003) Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21: 433–440
Bertoni AG et al. (2001) Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 24: 1044–1049
Ellis ME et al. (1986) Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study. Am J Clin Oncol 9: 533–536
Levetan CS et al. (1998) Unrecognized diabetes among hospitalized patients. Diabetes Care 21: 246–249
Sawin C and McCulloch D (online 5 November 2004) Management of diabetes mellitus in the acute care setting. [http://www.uptodate.com] (accessed 29 November 2004)
Levetan CS et al. (1995) Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med 99: 22–28
Harris MI and Eastman RC (2000) Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev 16: 230–236
Coughlin SS et al. (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159: 1160–1167
Verlato G et al. (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26: 1047–1051
Goodwin PJ et al. (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20: 42–51
Gurney H (2002) How to calculate the dose of chemotherapy. BJC 86: 1297–1302
Hewitt M et al. (2003) Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 58: 82–91
Yancik R et al. (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285: 885–892
Krinsley JS (2003) Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 78: 1471–1478
Saydah SH et al. (2001) Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 24: 447–453
Shaw JE et al. (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42: 1050–1054
Eyre H et al. (2004) Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. CA Cancer J Clin 54: 190–207
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Richardson, L., Pollack, L. Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Rev Clin Oncol 2, 48–53 (2005). https://doi.org/10.1038/ncponc0062
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0062
This article is cited by
-
Diabetes and Cancer Co-management Education: Leveraging the Patient Activated Learning System (PALS) for Patients with Breast Cancer
Journal of Cancer Education (2023)
-
The impact of the incidence of diabetic complications on mortality in colorectal cancer patients with diabetes: A nationwide study
International Journal of Colorectal Disease (2023)
-
The association between fasting blood glucose and prognosis in gastrointestinal stromal tumor patients after curable resection
Updates in Surgery (2023)
-
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
BMC Cancer (2022)
-
Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk
Scientific Reports (2022)